Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Bristol Myers Squibb Wins FDA Approval for Its First CELMoD Drug, Aimed at Multiple ...

15 August 2026 · By · Wire by Fusion42

Published

15 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at biobuzz.io →

◆ Verified

Fusion42 · 15 August 2026 · Fusion42 review

Bristol Myers Squibb received FDA accelerated approval for ZENBEXUS (iberdomide), its first CELMoD therapy, targeting multiple myeloma patients after just one relapse, offering a new treatment option and potential revenue growth for the company amid generic competition.

This Wire brief sits within Fusion42's coverage of Biotech, and 12 sources have reported it between 13 Aug 2026 and 17 Aug 2026.

◆ ◆ The Wire takeaway

New oral cancer drugs that use protein degradation open a revenue path for therapy developers replacing aging blockbusters. You can plan to engage oncologists early with these novel mechanisms, as competitors lose ground to generics.

◆ Coverage

12 sources · first reported 13 Aug 2026 · latest 17 Aug 2026

◆ Related on Wire

◆ Topics

Biotechdrug-approvalmultiple-myelomacelmodbmsfdaoncology